<DOC>
	<DOCNO>NCT00003740</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . PURPOSE : Phase II trial study effectiveness trastuzumab treat patient prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Trastuzumab Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I. Assess activity trastuzumab ( Herceptin ) patient progressive androgen dependent independent prostate cancer . II . Study HER2 status immunohistochemistry prostate cancer biopsy sample . III . Study association HER2 protein expression tumor cell post-therapy change PSA patient population . OUTLINE : Patients receive trastuzumab IV 30 90 minute week . Treatment continue maximum 24 week absence unacceptable toxicity disease progression . Patients follow time progression . PROJECTED ACCRUAL : A total 14-25 patient accrue study within 6-9 month .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically document androgen dependent independent prostate cancer Progressive disease primary hormonal treatment ( e.g. , orchiectomy , estrogen therapy , gonadotropin release hormone analog without antiandrogen ) New osseous lesion bone scan OR 25 % increase bidimensionally measurable soft tissue disease appearance new site disease MRI CT scan If initial hormonal treatment combine androgen blockade approach , must show progression antiandrogen Minimum 3 rise PSA value baseline obtain 1 week apart OR 2 rise PSA value obtain 2 week apart PSA least 4 ng/mL Testosterone great 30 ng/mL No active CNS epidural tumor PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 6 month Hematopoietic : WBC great 3,500/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2.0 mg/dL SGOT le 3 time upper limit normal PT le 14 second Renal : Creatinine le 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No myocardial infarction within prior 6 month No active angina pectoris , New York Heart Association class III IV heart disease , severe debilitate valvular disease Ejection fraction great 45 % , evidence ventricular aneurysm abnormal wall motion OR SESTAMIBI stress test must show fixed defect alone ejection fraction le 45 % , worrisome nonexclusive cardiovascular history , abnormal ECG Pulmonary : No severe pulmonary disease Other : Fertile patient must use effective contraception No history active secondary malignancy past 5 year except nonmelanoma skin cancer No infection require intravenous antibiotic treatment No severe medical problem would increase risk toxicity PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : At least 4 week since prior chemotherapy recover No concurrent chemotherapy Endocrine therapy : See Disease Characteristics If prior surgical orchiectomy , must continue medical therapy maintain castrate level testosterone Radiotherapy : At least 4 week since prior radiotherapy recover No concurrent radiotherapy Surgery : See Disease Characteristics Endocrine therapy No concurrent surgery Other : At least 4 week since prior investigational anticancer therapeutic drug recover No prior anthracycline anthracenedione No concurrent investigational unlicensed agent No concurrent oncolytic agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>